SCHEMBL2761629

SCHEMBL2761629

COC(=O)c1c(O)c2cc(OCC3CCCCC3)ccc2oc1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.47
TP53 P04637 2/20 0.47
HTT P42858 2/20 0.47
MEN1 O00255 1/20 0.47
CRHBP P24387 1/20 0.47
KMT2A Q03164 1/20 0.47
CRHR2 Q13324 1/20 0.47
PARP10 Q53GL7 5/20 0.46
PARP15 Q460N3 4/20 0.46
MAOB P27338 8/20 0.45
MAOA P21397 7/20 0.45
ACHE P22303 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
ESR1 P03372 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2761739 0.84 LMNA (0.44) LMNATP53HTTMEN1CRHBP
SCHEMBL2762082 0.84 LMNA (0.42) LMNATP53HTTMEN1CRHBP
SCHEMBL2762083 0.84 LMNA (0.42) LMNATP53HTTMEN1CRHBP
SCHEMBL2468684 0.79 PARP10 (0.46) PARP10PARP15MAOBMAOAL3MBTL1
SCHEMBL2761639 0.78 MAOB (0.60) LMNAHTTMEN1KMT2AMAOB
SCHEMBL2762010 0.78 L3MBTL1 (0.58) LMNAMEN1KMT2AMAOBMAOA
SCHEMBL2761878 0.76 NQO1 (0.49) LMNATP53HTTMEN1KMT2A
SCHEMBL26676564 0.76 TSHR (0.47) LMNATP53HTTMEN1KMT2A
SCHEMBL2761791 0.75 MAOB (0.52) LMNATP53HTTMEN1CRHBP
SCHEMBL348202 0.75 PARP10 (0.58) PARP10PARP15MAOBMAOAPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324405-B2 Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors FIBROGEN, INC. (US) 2012-12-04 US disclosed
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. 2010-12-30 US disclosed
WO-2009100250-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. (US) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS HIF1AN, HIF1A, EGLN2 LMNA 2624/4885TP53 1014/4885HTT 3262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.